


GENERAL CONFORMITY CERTIFICATE
Consumer Protection Safety Improvements Act (CPSIA)
15 U.S.C. § 2063(a)

The Manufacturer below certifies that the product identified below is in compliance with applicable CPSC-enforced safety rules.

<p>1. Specific product covered by this certificate:</p> <p>Adlyxin™ (lixisenatide injection) NDC # 00024-5745-02</p>
<p>2. Specific regulation(s), rules, bans, and/or standards for which this product is being certified:</p> <p>16 CFR §§ 1700.14(a) & 1700.15</p>
<p>3. Manufacturer or importer certifying compliance:</p> <p>Name: Sanofi US Mailing address: 55 Corporate Drive, Bridgewater, NJ 08807 Telephone number: 1-800-372-6634</p>
<p>4. Individual maintaining records of the test results upon which this certification is based:</p> <p><u>Name and/or title:</u> Mark DeSieno Sr. Director, Industrial Development, Industrial Affairs 55 Corporate Drive, Bridgewater, NJ 08807</p> <p><u>For information contact:</u> Phone: 1-908-981-3922 Email: mark.desieno@sanofi.com</p>
<p>5. Date and place where this product was packaged:</p> <p>Products are packaged at one or more locations. For information on the date and place of packaging of a specific product, please contact us at 1-800-372-6634 or TradeCustomerSupport@sanofi.com, with the Lot number and Expiration Date from the product container.</p>
<p>6. Date and place where this product was tested for compliance and third party laboratory(ies) that conducted testing upon which this certification is based.</p> <p><u>Date of test reports:</u> N/A <u>Name and Mailing Address of Testing Laboratory:</u> N/A</p> <p>If box is checked, then product testing requirements were not applicable <input checked="" type="checkbox"/></p> <p>Approved: <u></u> Date: <u>20 Sept 2018</u></p> <p style="text-align: center;">Sr. Director, Industrial Development, Industrial Affairs</p>